Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
16 Mayo 2024 - 6:00AM
Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage
biopharmaceutical company aiming to transform the lives of patients
by establishing a new class of medicines that engage intracellular
targets long considered inaccessible. The Company today announced
that Dipal Doshi, Chief Executive Officer, will participate in a
fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor
Conference at NASDAQ in New York, NY. The fireside chat will be
held on Monday, May 20, 2024, at 9:30 a.m. Eastern Time.
A live webcast will be available on the Investor Relations
section of the Company’s website at www.entradatx.com. A replay
will be available on the Entrada website for 90 days following the
event.
About Entrada Therapeutics Entrada Therapeutics
is a clinical-stage biopharmaceutical company aiming to transform
the lives of patients by establishing a new class of medicines that
engage intracellular targets long considered inaccessible. The
Company’s Endosomal Escape Vehicle (EEV™)-therapeutics are designed
to enable the efficient intracellular delivery of a wide range of
active moieties into a variety of organs and tissues, resulting in
an improved therapeutic index. Through this proprietary, versatile
and modular approach, Entrada is advancing a robust development
portfolio of RNA-, antibody- and enzyme-based programs for the
potential treatment of neuromuscular, ocular, metabolic and
immunological diseases, among others. The Company’s lead
oligonucleotide programs are in development for the treatment of
people living with Duchenne muscular dystrophy who are exon 44, 45
and 50 skipping amenable. Entrada has partnered VX-670, a
clinical-stage program for the treatment of myotonic dystrophy type
1.
For more information about Entrada, please visit our
website, www.entradatx.com, and follow us on LinkedIn.
Investor and Media ContactKarla MacDonaldChief
Corporate Affairs Officerkmacdonald@entradatx.com
Entrada Therapeutics (NASDAQ:TRDA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Entrada Therapeutics (NASDAQ:TRDA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024